Reviva Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.88% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.37%.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.18%.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.40%.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 0.00%.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.88% 10-Q · filed 2026-08-12 | |||
| 2025-09-30 | 3.37% 10-Q · filed 2025-11-13 | 4.39% 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 4.18% 10-Q · filed 2025-08-14 | 4.39% 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | 4.40% 10-Q · filed 2025-05-15 | |||
| 2024-09-30 | 3.37% 10-Q · filed 2024-11-14 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-04-03 | |||
| 2023-09-30 | 3.43% 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 3.43% 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-04-15 | |||
| 2022-09-30 | 2.95% 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |